Melchor Lim, MD
Cardiovascular Disease · Stillwater, OKNPI 1932147113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,286 and has fallen 66.5% since, to $431 in 2025.
Across 386 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$877
- Johnson & Johnson$603
- E.r. Squibb & Sons, L.L.C.$438
- Amarin Pharma, Inc.$386
- Merck$378
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,86599%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 79 | $1,238 |
| Pfizer | 58 | $877 |
| Johnson & Johnson | 43 | $603 |
| E.r. Squibb & Sons, L.L.C. | 38 | $438 |
| Amarin Pharma, Inc. | 30 | $386 |
| Merck | 25 | $378 |
| Abbott | 21 | $354 |
| AstraZeneca | 10 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $151 |
| Boehringer Ingelheim | 9 | $137 |
| Sanofi-aventis U.S. LLC | 7 | $135 |
| Actelion Pharmaceuticals US, Inc. | 5 | $120 |
| Kestra Medical Technology Services, Inc. | 6 | $111 |
| Regeneron Healthcare Solutions, Inc. | 7 | $110 |
| Bayer | 7 | $100 |
| Alnylam Pharmaceuticals Inc. | 2 | $87 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| Boston Scientific | 3 | $73 |
| Astellas Pharma US Inc | 2 | $65 |
| Lexicon Pharmaceuticals, Inc. | 3 | $53 |
| Amgen | 3 | $48 |
| Abiomed | 1 | $38 |
| Novo Nordisk | 2 | $31 |
| Biosense Webster, Inc. | 1 | $26 |
| Innovation Technologies Inc | 1 | $20 |
| United Therapeutics Corporation | 1 | $20 |
| Insmed, Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$5,940 in reported general payments places this provider in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 393 | $320,823 |
| EntrestoSacubitril/Valsartan | 108 | $114,075 |
| XareltoRivaroxaban | 77 | $72,625 |
| FarxigaDapagliflozin Propanediol | 64 | $57,154 |
| VascepaIcosapent Ethyl | 50 | $20,151 |
| JardianceEmpagliflozin | 36 | $16,683 |
| Icosapent Ethyl | 46 | $11,779 |
| Ezetimibe | 407 | $9,623 |
| Rosuvastatin Calcium | 592 | $8,672 |
| BrilintaTicagrelor | 16 | $8,032 |
| Atorvastatin Calcium | 525 | $7,084 |
| Metoprolol Succinate | 460 | $7,036 |
| Carvedilol | 624 | $6,804 |
| Ranolazine ErRanolazine | 79 | $6,475 |
| Flecainide Acetate | 98 | $5,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $877 | $320,823393 claims |
| NovartisEntresto | $1,238 | $114,075108 claims |
| Johnson & JohnsonXarelto | $603 | $72,62577 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $159 | $66,58892 claims |
| Boehringer IngelheimJardiance | $137 | $16,68336 claims |
| AmgenCorlanor | $48 | $5,75216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Stillwater
- James HarrisStillwater$10K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.